pembrolizumab
merck
['tnbc', 'pembro', 'bcsm']
dr. lajos pusztai will present an analysis of #keynote522 highlighting "event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early #tnbc" at #asco22 today at 10:33amcdt in halld1. #bcsm 
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.